Shire Releases 2015 Annual Responsibility Review

Primary tabs

Shire Releases 2015 Annual Responsibility Review

Monday, April 11, 2016 - 9:00am

CONTENT: Blog

We’re proud of the progress we are making.

Responsibility has always been embedded in our business. It underpins our daily work, our decisions, and our relationships and remains with us as we move even further into complex and challenging areas. Our commitment to Responsibility remains steadfast.

Now more than ever, our primary responsibility is to our patients; helping them access the medicines they need and addressing otherwise unmet medical needs, particularly around rare disease therapies. We do not work in isolation, however, and we are dedicated to working with healthcare professionals, advocacy organizations, and governments to maximize our potential in making a meaningful difference to patients across the world.

We also recognize that our people are crucial to executing our strategy to become a leading global biotech focused on rare diseases and specialty conditions. We believe that being a responsible company will help us attract, develop, and retain the world-class talent we need to achieve our goals.

We are pleased that our efforts to improve our approach to Responsibility have not gone unnoticed. I am proud that this year we moved up 10 places in the Global 100 Sustainability Index. Shire ranked 52nd overall in the index and 2nd among all pharmaceutical companies. We have also been confirmed, once again, as a constituent in the FTSE4Good Index Series and ranked as the 2nd “greenest” company in the world by Newsweek magazine.

I am proud of this continued progress and congratulate everyone at Shire for our achievements. But I am keenly aware that we cannot rest and must continue to move forward. This review highlights the issues that matter most to Shire, to our employees, our external stakeholders and most importantly, our patients. It details our work to address these issues and the plans we are making to continue improving our performance in the coming years.

Sincerely,

Flemming Ornskov, MD, MPH
Chief Executive Officer

To read more, please download Shire’s 2015 Annual Responsibility Review.

Keywords: Research, Reports & Publications | Access to Medicines | Corporate Social Responsibility | Environment | Health & Healthcare | Philanthropy & Cause Initiatives | Shire Pharmaceuticals | Social Impact & Volunteering | rare diseases | sustainability

CONTENT: Blog